Aurobindo Pharma has received final approval from the United State Food and Drug Administration (USFDA) for 30 mg and 40 mg Stavudine tablets.This is the first generic approval received by the company and fourth anti-retroviral abbrreviated new drug application (ANDA) approved by the USFDA, Aurobindo informed the BSE .today.The company has already got approval for Nevirapine, Lamivudine and Efavirenz, the release said.Stavudine is an antiviral agent of the nucleoside analog class, which includes Zidovudine (AZT), Didanosine (DDL) and Zalcitabine (DDC). The international brand name is Zerit and is marketed by Bristol Myers Squibb, it said.The drug would now be available for consideration for purchase under the US president's emergency plan for AIDS relief (Pepfar), the 5-year programme being run to fight HIV/AIDS pandemic, the release added.
